Purification of specific antibody to alpha-foetoprotein and its immunological effect on cancer cells.
Human of rat alpha-foetoprotein (AFP) was highly purified from ascitic fluid or serum of hepatoma bearers. The purification was carried out mainly by means of immunoadsorbent chromatography using Sepharose coupled to specific anti-AFP antibody with BrCN activation, and by Sephadex gel filtration. Horses were immunized with the purified AFP and the specific antibody was isolated from the antiserum by means of an immunoadsorbent coupled to purified AFP. The specific antibody was found to bind specifically with AFP-producing tumour cells. The antibody was applied for radio immunodetection of the tumour. 125I-labelled antibody was administered to patients or rats with hepatoma, and radioactivity localized in the tumours was scintiscanned with a scintillation camera. In this way, the location of the tumour was detected in about 50% of the hepatoma bearers. The cytotoxicity of the antibody was clearly demonstrated both in vitro and in vivo in animal experiments. The antibody was administered to patients with advanced hepatoma. Although no improvement of the disease was demonstrated, serum AFP levels decreased greatly and in some cases low AFP levels were maintained for long periods suggesting that the antibody suppressed AFP-producing hepatoma cells. No significant side effects were observed in patients who had been administered with the horse antibody.
D000818:Animals; D000906:Antibodies / Q000008:administration & dosage; D000917:Antibody Formation; D001202:Ascitic Fluid / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000628:therapy; D006801:Humans; D008113:Liver Neoplasms; D008114:Liver Neoplasms, Experimental / Q000097:blood / Q000139:chemically induced / Q000276:immunology; D051381:Rats; D000509:alpha-Fetoproteins / Q000276:immunology / Q000302:isolation & purification*
D000906:Antibodies; D000509:alpha-Fetoproteins